Request Trial
brown-eye-close-up
5 August 2013Big Pharma

Roche signs drug licensing agreement with MPP

On August 5, Swiss pharmaceutical company Roche signed an agreement with the Medicines Patent Pool (MPP) to increase access to its drug valganciclovir (Valcyte), an oral medicine for the treatment of preventable viral infection cytomegalovirus (CMV).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UKIPO extends funding for specialist IP crime unit as counterfeit risks grow
10 March 2026   UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.
Big Pharma
The curtain closes on three major drug disputes
11 February 2026   Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.


Editor's picks

Abbott IP chief: ‘Firms without AI policies scare me’
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

Editor's picks

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

More features

GSK inks licensing deal for liver disease drug
Arnold & Porter adds tech litigator in San Francisco
Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs
UKIPO extends funding for specialist IP crime unit as counterfeit risks grow
Medtech Magnolia fails to revive $2.1m verdict at Fed Circ
Nomination call: Influential Women in IP list closes ahead of International Women’s Day
Abbott IP chief: ‘Firms without AI policies scare me’
Moderna inks billion-dollar deal to settle long-running Spikevax dispute